IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans Series 91

Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy

December 2008
More details
  • Publisher
    World Health Organization
  • Published
    18th December 2008
  • ISBN 9789283212911
  • Language English
  • Pages 537 pp.
  • Size 6.75" x 9.5"
  • Images tables and charts

This ninety-first volume of IARC Monographs contains evaluations of the carcinogenic hazard to humans of combined estrogen-progestogen contraceptives and combined estrogen-protestogen menopausal therapy.

The hormonal drugs reviewed in this volume involve co-administration of an estrogen and a progestogen.
Studies that did not provide information on the use of combined estrogen-progestogen agents are not reviewed.
It should also be noted that this volume reviews only studies that are publicly available and therefore does not include pharmaceutical test results that are not in the public domain.

The evaluations developed in this volume identify specific forms of cancer for which the risk is increased or decreased by combined estrogen-progestogen contraceptives and provide information that will help address the health concerns and well-being of hundred of millions of women worldwide.

Note to the Reader
List of Participants
General Remarks
The Monographs
Combined Estrogen - Progestogen Contraceptives
Combined Estrogen - Progestogen Menopausal Therapy
Annexes 1-4
List of Abbreviations
Cumulative Index to the Monographs Series

The International Agency for Research on Cancer

The International Agency for Research on Cancer (IARC) is part of the World Health Organization. IARC's mission is to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control. The Agency is involved in both epidemiological and laboratory research and disseminates scientific information through publications, meetings, courses, and fellowships.